Efficacy of PLD Monotherapy in HER2-Negative MBC

This was a prospective, single-center, open-label, single-arm, phase II study designed to evaluate the efficacy and safety of PLD 40 mg/m² every 4 weeks monotherapy in patients with HER2-negative MBC pretreated with conventional anthracycline and taxanes. Patients received PLD (Duomeisu^®) 40 mg/m² diluted in 250 mL of 5% dextrose intravenous infusion for 1 h on day 1 of each 28-day cycle. The detailed dose adjustment schemes were presented in Supplemental Methods. Treatment was continually administered until disease progression, unacceptable toxicity, treatment delay of > 3 weeks owing to toxicity, completion of 6 cycles, or patient’s decision to withdraw from the study.